Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	3	JAN 16	CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS	4	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	5	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	6	JAN 22	CA/CAplus updated with revised CAS roles
NEWS	7	JAN 22	CA/CAplus enhanced with patent applications from India
NEWS	8	JAN 29	PHAR reloaded with new search and display fields
NEWS	9	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	10	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	11	FEB 15	RUSSIAPAT enhanced with pre-1994 records
NEWS	12	FEB 23	KOREAPAT enhanced with IPC 8 features and functionality
NEWS	13	FEB 26	MEDLINE reloaded with enhancements
NEWS	14	FEB 26	EMBASE enhanced with Clinical Trial Number field
NEWS	15	FEB 26	TOXCENTER enhanced with reloaded MEDLINE
NEWS	16	FEB 26	IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS	17	FEB 26	CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS	18	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	19	MAR 16	CASREACT coverage extended
NEWS	20	MAR 20	MARPAT now updated daily
NEWS	21	MAR 22	LWPI reloaded
NEWS	22	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	23	MAR 30	INPADOCDB will replace INPADOC on STN
NEWS	24	APR 02	JICST-EPLUS removed from database clusters and STN

NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:53:39 ON 25 APR 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:53:49 ON 25 APR 2007

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 APR 2007 HIGHEST RN 932392-31-9
DICTIONARY FILE UPDATES: 24 APR 2007 HIGHEST RN 932392-31-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10573204.str





chain nodes :
10 11 18 19 20 21 22 23 24 27
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
chain bonds :
8-10 9-19 10-11 10-20 10-27 11-12 11-21 11-22 13-23 15-24 16-18
ring bonds :
1-2 1-6 2-3 3-4 3-7 4-5 4-9 5-6 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
3-7 4-9 7-8 8-9 10-27 16-18
exact bonds :
8-10 9-19 10-11 10-20 11-12 11-21 11-22 13-23 15-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 : 12 :

G1:C,H

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 27:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,H

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 12:54:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 8 TO 329
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 12:54:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 163 TO ITERATE

100.0% PROCESSED 163 ITERATIONS 27 ANSWERS
SEARCH TIME: 00.00.01

L3 27 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 12:54:35 ON 25 APR 2007

FILE COVERS 1907 - 25 Apr 2007 VOL 146 ISS 18
FILE LAST UPDATED: 24 Apr 2007 (20070424/ED)

=> s l3 full
L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:43156 CAPLUS
DOCUMENT NUMBER: 144:163527
TITLE: The novel imidazopyridine 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) is a highly selective inhibitor of the inducible nitric-oxide synthase
AUTHOR(S): Strub, Andreas; Ulrich, Wolf-Ruediger; Hesslinger, Christian; Eltze, Manfrid; Fuchss, Thomas; Strassner, Jochen; Strand, Susanne; Lehner, Martin D.; Boer, Rainer
CORPORATE SOURCE: Departments of Biochemistry, Chemistry and Pharmacology, ALTANA Pharma AG, Konstanz, Germany
SOURCE: Molecular Pharmacology (2006), 69(1), 328-337
CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We have identified imidazopyridine derivs. as a novel class of NO synthase inhibitors with high selectivity for the inducible isoform. 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) showed half-maximal inhibition of crudely purified human inducible (iNOS), neuronal (nNOS), and endothelial (eNOS) NO synthases at 86 nM, 17 μM, and 162 μM, resp. Inhibition of inducible NO synthase was competitive with L-arginine, pointing to an interaction of BYK191023 with the catalytic center of the enzyme. In radioligand and surface plasmon resonance expts., BYK191023 exhibited an affinity for iNOS, nNOS, and eNOS of 450 nM, 30 μM, and >500 μM, resp. Inhibition of cellular nitrate/nitrite synthesis in RAW, rat mesangium, and human embryonic kidney 293 cells after iNOS induction showed 40- to 100-fold higher IC50 values than at the isolated enzyme, in agreement with the much higher L-arginine concns. in cell culture media and inside intact cells. BYK191023 did not show any toxicity in various rodent and human cell lines up to high micromolar concns. The inhibitory potency of BYK191023 was tested in isolated organ models of iNOS (lipopolysaccharide-treated and phenylephrine-precontracted rat aorta; IC50 = 7 μM), eNOS (arecaidine propargyl ester-induced relaxation of phenylephrine-precontracted rat aorta; IC50 > 100 μM), and nNOS (field-stimulated relaxation of phenylephrine-precontracted rabbit corpus cavernosum; IC50 > 100 μM). These data confirm the high selectivity of BYK191023 for iNOS over eNOS and nNOS found at isolated enzymes. In summary, we have identified a new

highly selective iNOS inhibitor structurally unrelated to known compds. and L-arginine. BYK191023 is a valuable tool for the investigation of iNOS-mediated effects in vitro and in vivo.

IT 857379-46-5, BYK 237007
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure activity relationship studied of imidazopyridine compds. as selective inhibitors of nitric-oxide synthase isoforms)

RN 857379-46-5 CAPLUS

CN 2-Pyridinamine, 6-[2-(1H-imidazo[4,5-b]pyridin-2-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:588961 CAPLUS
DOCUMENT NUMBER: 143:115536
TITLE: A preparation of (aminopyridinylethyl)imidazolopyridine derivatives, useful as inductible NO-synthase inhibitors
INVENTOR(S): Boer, Rainer; Marx, Degenhard; Ulrich, Wolf-Ruediger; Eltze, Manfrid; Nave, Ruediger; Strub, Andreas; Graedler, Ulrich; Fuchss, Thomas
PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061496	A1	20050707	WO 2004-EP52373	20040930
WO 2005061496	A8	20060216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303515	A1	20050707	AU 2004-303515	20040930
CA 2540230	A1	20050707	CA 2004-2540230	20040930
EP 1670798	A1	20060621	EP 2004-820599	20040930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1856493	A	20061101	CN 2004-80027807	20040930
BR 2004015034	A	20061212	BR 2004-15034	20040930
JP 2007507464	T	20070329	JP 2006-530261	20040930
US 2007043072	A1	20070222	US 2006-573204	20060324

NO 2006001789	A	20060424	NO 2006-1789		20060424
PRIORITY APPLN. INFO.:			EP 2003-22040	A	20031001
			WO 2004-EP52373	W	20040930

OTHER SOURCE(S): MARPAT 143:115536
GI



I



II

AB The invention relates to a preparation of (aminopyridinylethyl)imidazolopyridine derivs. of formula I [wherein: R1 is H or alkyl; R2 is H, halogen, NH2, (cyclo)alkyl, or CF3, etc.; R3 is H, halogen, alkyl, or alkoxyl R4 is alkyl or alkoxy], useful as antiinflammatory agents (inductible NO-synthase inhibitors). For instance, (aminopyridinylethyl)imidazolopyridine derivative II was prepared via condensation of 4-methyl-2-(tritylamino)picolinaldehyde with [3H-imidazo[4,5-b]pyridin-2-ylmethyl]triphenylphosphonium chloride and subsequent reduction of the obtained intermediate. The invention compds. were tested for NO-synthase activity [-logIC50(mol/L) values range from 6.58 to 8.15].

IT 857379-53-4P 857379-56-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of (aminopyridinylethyl)imidazolopyridine derivs. useful as inductible NO-synthase inhibitors)

RN 857379-53-4 CAPLUS
CN 2-Pyridinamine, 6-[2-(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-56-7 CAPLUS
CN 2-Pyridinamine, 4-methyl-6-[2-(6-phenyl-1H-imidazo[4,5-b]pyridin-2-yl)ethyl]- (9CI) (CA INDEX NAME)



IT 857379-46-5P 857379-49-8P 857379-50-1P
857379-51-2P 857379-57-8P 857379-58-9P
857379-61-4P 857379-63-6P 857379-65-8P
857379-66-9P 857379-68-1P 857379-69-2P
857379-71-6P 857379-72-7P 857379-73-8P
857379-74-9P 857379-75-0P 857379-76-1P
857379-77-2P 857379-78-3P 857379-79-4P
857379-81-8P 857380-22-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (aminopyridinylethyl)imidazolopyridine derivs. useful as inductible NO-synthase inhibitors)

RN 857379-46-5 CAPLUS
CN 2-Pyridinamine, 6-[2-(1H-imidazo[4,5-b]pyridin-2-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-49-8 CAPLUS
CN 2-Pyridinamine, 6-[2-(1H-imidazo[4,5-b]pyridin-2-yl)ethyl]-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 857379-50-1 CAPLUS
CN 2-Pyridinamine, 6-[2-(1H-imidazo[4,5-b]pyridin-2-yl)ethyl]-4-methyl-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 857379-46-5
CMF C14 H15 N5



CM 2

CRN 64-19-7
CMF C2 H4 O2



RN 857379-51-2 CAPLUS
CN 2-Pyridinamine, 6-[2-(1H-imidazo[4,5-b]pyridin-2-yl)propyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-57-8 CAPLUS
CN Benzonitrile, 4-[2-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 857379-58-9 CAPLUS
CN 2-Pyridinamine, 4-methyl-6-[2-[6-(4-methylphenyl)-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 857379-61-4 CAPLUS
CN 2-Pyridinamine, 6-[2-[6-(4-fluorophenyl)-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-63-6 CAPLUS
CN 2-Pyridinamine, 6-[2-[6-[4-(dimethylamino)phenyl]-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-65-8 CAPLUS
CN 2-Pyridinamine, 6-[2-[6-[4-(dimethylamino)phenyl]-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 857379-66-9 CAPLUS
CN 2-Pyridinamine, 6-[2-[6-(4-chlorophenyl)-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-68-1 CAPLUS
CN 2-Pyridinamine, 6-[2-[6-(4-chlorophenyl)-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-4-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 857379-69-2 CAPLUS
CN 2-Pyridinamine, 6-[2-[6-(4-iodophenyl)-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-71-6 CAPLUS
CN 2-Pyridinamine, 4-methyl-6-[2-[6-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 857379-72-7 CAPLUS
CN 2-Pyridinamine, 4-methyl-6-[2-[6-[3-(phenylmethoxy)phenyl]-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 857379-73-8 CAPLUS
CN 2-Pyridinamine, 6-[2-[6-(3,5-dichlorophenyl)-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-74-9 CAPLUS
CN 2-Pyridinamine, 4-methyl-6-[2-[6-[4-(phenylmethoxy)phenyl]-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 857379-75-0 CAPLUS
CN Phenol, 3-[2-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)



RN 857379-76-1 CAPLUS
CN Pyrrolidine, 1-[[4-[2-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 857379-77-2 CAPLUS
CN Piperidine, 1-[[4-[2-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 857379-78-3 CAPLUS
CN Benzenesulfonamide, 4-[2-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 857379-79-4 CAPLUS
CN Piperazine, 1-[[4-[2-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 857379-81-8 CAPLUS
CN 2-Pyridinamine, 6-[2-(1H-imidazo[4,5-b]pyridin-2-yl)ethyl]-4-methoxy-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 857379-80-7
CMF C14 H15 N5 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 857380-22-4 CAPLUS
CN Azetidine, 1-[[4-[2-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-1H-imidazo[4,5-b]pyridin-6-yl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



IT 857379-60-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of (aminopyridinylethyl)imidazolopyridine derivs. useful as inductible NO-synthase inhibitors)
RN 857379-60-3 CAPLUS
CN 2-Pyridinamine, 4-methyl-6-[2-[6-(4-methylphenyl)-1H-imidazo[4,5-b]pyridin-2-yl]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 12:53:39 ON 25 APR 2007)

FILE 'REGISTRY' ENTERED AT 12:53:49 ON 25 APR 2007
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 27 S L1 FULL

FILE 'CAPLUS' ENTERED AT 12:54:35 ON 25 APR 2007
L4 2 S L3 FULL

=> log y
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST	11.01	183.32
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

STN INTERNATIONAL LOGOFF AT 12:55:20 ON 25 APR 2007